• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Provident Financial Services

Provident Financial Services

Fidelity Advisor Asset Manager® 50% T FFTMX 2 Star

Last Price$17.38Day Change (%)-0.06%
Open Price$17.38Day Change ($)-0.01
Day Range17.38–17.3852-Week Range15.98–17.39

As of Fri 04/21/2017 | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Global Market for Printable, Flexible and Stretchable Sensors and Electronics 2017-2027 - Research and Markets

    Global Market for Printable, Flexible and Stretchable Sensors and Electronics 2017-2027 - Research and Markets

  2. Chugai's Alecensa® Met Its Primary Endpoint in the ALEX Study

    Chugai's Alecensa® Met Its Primary Endpoint in the ALEX Study

  3. Phase III Study Shows Genentech’s Alecensa® Was Superior to Crizotinib in a Specific Type of Lung Cancer

    Phase III Study Shows Genentech’s Alecensa® Was Superior to Crizotinib in a Specific Type of Lung Cancer

  4. Chi-Med Presented Pre-clinical Data for Fruquintinib and Sulfatinib at the American Association for Cancer Research Annual Meeting 2017

    Chi-Med Presented Pre-clinical Data for Fruquintinib and Sulfatinib at the American Association for Cancer Research Annual Meeting 2017

  5. Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting

    Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting

  6. ERYTECH Reports Positive Phase 2b Data for eryaspase for the Treatment of Metastatic Pancreatic Cancer

    ERYTECH Reports Positive Phase 2b Data for eryaspase for the Treatment of Metastatic Pancreatic Cancer

  7. IBRANCE® (palbociclib) Receives FDA Regular Approval and Expanded Indication for First-Line HR+, HER2- Metastatic Breast Cancer

    IBRANCE® (palbociclib) Receives FDA Regular Approval and Expanded Indication for First-Line HR+, HER2- Metastatic Breast Cancer

  8. TAGRISSO® (osimertinib) Receives US FDA Full Approval

    TAGRISSO® (osimertinib) Receives US FDA Full Approval

  9. AstraZeneca Shares Progress on LYNPARZA™ (olaparib) Tablets in the US

    AstraZeneca Shares Progress on LYNPARZA™ (olaparib) Tablets in the US

  10. NAPFA’s CFP-Only Stand: A Step in the Wrong Direction

    A curious move, at a curious time, for purportedly, a curious reason, that is also a slap in the face to CPAs with the PFS credential.

123

©2017 Morningstar Advisor. All right reserved.